HIV-1 protease (PR) cleavage of the Gag polyprotein triggers the assembly of mature, infectious particles. Final cleavage of Gag occurs at the junction helix between the capsid protein CA and the SP1 spacer peptide. Here we used MicroED to delineate the binding interactions of the maturation inhibitor bevirimat (BVM) using very thin frozen-hydrated, three-dimensional microcrystals of a CTD-SP1 Gag construct with and without bound BVM. The 2.9-Å MicroED structure revealed that a single BVM molecule stabilizes the 6helix bundle via both electrostatic interactions with the dimethysuccinyl moiety and hydrophobic interactions with the pentacyclic triterpenoid ring. These results provide insight into the mechanism of action of BVM and related maturation inhibitors that will inform further drug discovery efforts. This study also demonstrates the capabilities of MicroED for structure-based drug design.
HIV-1 Gag and Gag-Pol assemble and bind the plasma membrane of infected cells 4 . The packing interactions between Gag hexamers induces positive membrane curvature, and engagement of cellular ESCRT complexes results in budding and release of immature HIV-1 virus particles comprised of the membrane-encased shell formed by the Gag lattice and the viral RNA. In the immature virion, Gag hexamers form a fissured, spherical shell with quasihexagonal symmetry on the inner leaflet of the viral envelope [5] [6] [7] . HIV-1 viral protease (PR) is liberated from Gag-Pol by autoproteolysis at a late stage of viral assembly, which ensures that Gag molecules are not processed before assembly of the lattice. All five Gag processing sites are essential for infectivity, and the sites are processed at different rates, in the order: SP1-NC > MA-CA ~ SP2-P6 > NC-SP2 > CA-SP1. The final, CA-SP1 cleavage triggers the dramatic morphological changes between immature and mature infectious HIV-1 particles that contain the characteristic conical capsid 8, 9 . Inhibition of Gag cleavage effectively prevents HIV-1 replication, and two therapeutic strategies have been pursued: protease inhibitors that bind directly to PR, and maturation inhibitors, which interfere with PR cleavage of Gag. The first characterized maturation inhibitor was bevirimat (BVM), which acts by preventing PR cleavage between residues L363 and A364 in the junction helix formed by the C-terminal domain of CA and SP1 spacer peptide, thereby stabilizing the immature lattice 10 11 However, the mechanism by which BVM stabilizes the immature lattice is unclear. Although BVM entered clinical trials, efficacy was thwarted by the presence of preexisting resistant viruses containing SP1 polymorphisms 12, 13 . Second generation maturation inhibitors have improved resistance profiles 14 15 , but rational drug development has been impeded by a lack of high-resolution structural data on maturation inhibitor binding to Gag.
In 2016, compelling evidence for the predicted 6-helix bundle structure of the junction helices was provided by electron cryotomography and subtomogram averaging of ΔMA-Gag, non-enveloped virus-like particles (VLPs) 16 , X-ray crystallography of a Gag construct comprised of the C-terminal domain (CTD) of CA and SP1 17 , and solid-state NMR spectroscopy of ΔMA-Gag VLPs 18 . The cryoEM and X-ray structures revealed that the protease cleavage sites are sequestered on the interior of the 6-helix bundle. The cryoEM map also showed that a single molecule of the maturation inhibitor bevirimat (BVM) binds at the center of each 6-helix bundle.
To achieve a resolution of 3.9 Å, 6-fold averaging was applied to the cryoEM map, which prevented characterization of the interactions between BVM and the CTD-SP1 junction helices.
Here we used MicroED [19] [20] [21] [22] [23] to delineate the binding interactions of BVM using very thin frozen-hydrated, three-dimensional microcrystals of the CTD-SP1 Gag construct. The protein was expressed and purified as described previously 17 , and the crystallization conditions were adapted to grow microcrystals < 1 µm thick (as described in the Materials and Methods and Supplementary Fig. 1 ). We solved the structures of drug-free and BVM-bound CTD-SP1 by MicroED (i.e., electron diffraction from frozen-hydrated, three-dimensional microcrystals) to resolutions of 3.0 Å and 2.9 Å, respectively (Table S1) , without applying 6-fold symmetry.
RESULTS
The CTD-SP1 crystals were of the same form that was used to solve the drug-free X-ray crystallographic structure to 3.27 Å resolution 17 . The asymmetric unit contains one CTD-SP1 hexamer, and layers of the C2 crystals approximate the HIV-1 Gag immature lattice ( Fig. 1) .
Molecular replacement phasing of the CTD-SP1-BVM MicroED data with the CTD X-ray structure (PDB 5I4T) resulted in a map that contains BVM density at the center of the 6-helix bundle formed by the CTD-SP1 junction helices ( Fig. 1d-f ). The density attributed to BVM is absent in our MicroED map of drug-free CTD-SP1 ( Fig. 1a-c) . The location of the single BVM molecule within the 6-helix bundle is consistent with a 3.9-Å map of HIV-1 Gag virus like particles (VLPs) determined by electron cryotomography and subtomogram averaging 16 .
In the case of the cryoEM map of VLPs, the BVM density was a featureless ellipsoid due to 6-fold averaging required to achieve a resolution of 3.9 Å for the protein density. However, 6fold averaging was not applied in the determination of the CTD-SP1-BVM MicroED map, and the BVM density is asymmetric with a dominant feature consistent with en face (Fig. 2c) and profile ( Fig. 2d ) views of the pentacyclic triterpenoid moiety of BVM. The presence of a unique mode of binding is presumably a consequence of the two-fold symmetric crystallographic environment of the binding site ( Fig. 1e) .
The location of the pentacyclic triterpenoid adjacent to the junction helices clearly indicates that hydrophobic interactions are important for the mechanism of binding of BVM ( Fig. 3e,f) . However, the primary drug density of the ring structure does not define the axial orientation of the bound drug, i.e., whether the dimethylsuccinyl group is oriented toward (BVM-up) or away from (BVM-down) the CA domain ( Supplementary Fig. 2 ). Regardless of the axial orientation, the hydrophobic interactions between BVM and Gag are confined to the junction helices. Specifically, L363 and M367 from each of the six protomers contribute the majority of the BVM binding interactions (Fig. 2c, d 
and f).
The axial orientation of the BVM is suggested by a satellite density directed toward the CA domain, which we ascribe to the dimethylsuccinyl moiety ( Fig. 2a-e ). This BVM-up orientation places the carboxylic acid of the dimethylsuccinyl moiety in proximity with a ring of lysine residues (K359). Notably, the extent of the density of the K359 side chains varies between protomers in the BVM-bound map. In particular, the side chain density is better defined for the K359 residue that is closest to the density peak we ascribe to the dimethylsuccinyl ( Fig. 2e,g) . In contrast, density for the K359 side chain is absent in 5 of 6 protomers in the drug-free CTD-SP1 map ( Fig. 2h) , likely due to conformational flexibility. The presence of density for the 6 dimethylsuccinyl carboxylate of BVM may seem surprising since acidic side chains frequently have diminished density in cryoEM maps 24 . However, proximity to the K359 ring of lysine likely neutralizes the Coloumb potential of the carboxylate, rendering it less susceptible to the nuances of electron scattering (for a detailed discussion see Supplementary Methods and Supplementary   Fig. 3 ).
Refinement of the structure with BVM in the up orientation also supports our interpretation ( Supplementary Fig. 2a ), whereas refinement with BVM in the down orientation positions the C-28 carboxyl more than 7 Å away from the nearest K359 Nζ, and the dimethylsuccinyl extends out of the junction helix bundle (Supplementary Fig. 2b,c) .
DISCUSSION
BVM is known to act by stabilizing the immature Gag lattice 11 , and the BVM dimethsuccinyl ester is thought to contribute to the activity 15 . It is possible that BVM stabilizes Gag hexamers by electrostatically anchoring to K359 of the CA CTD domain via the dimethylsuccinyl carboxylate ( Fig. 3c,d) and binding together the junction helices via hydrophobic interactions between L363 and M367 from each protomer and the BVM pentacyclic triterpenoid moiety ( Fig. 3e,f ). This BVM binding mechanism could accommodate lattice and hexamer distortions due to the non-specific nature of the hydrophobic interactions and the electrostatic attraction with the six K359 residues, which is amplified by a second, coaxial ring of lysine residues (K290) ( Fig. 2c,d) .
This mechanism of BVM binding and Gag stabilization is also consistent with the structures of second-generation HIV-1 maturation inhibitors in which the dimethylsuccinyl ester is replaced with benzoic acid (Supplementary Fig. 4 ). C-3 benzoic acid substitution places a carboxyl in proximity to K359 while preserving the hydrophobic interactions between the 7 junction helices and the pentacyclic triterpenoid. The fact that the C-3 benzoic acid substituted compound exhibited antiviral activity comparable to BVM and had no effect on the potency against the BVM Gag escape mutant V370A provides additional support for BVM binding with the succinic acid positioned in the vicinity of K359 and away from V370. In addition, the BVMup orientation positions C-28 of BVM near M367, and C-28 derivatives that extend BVM analogs toward the C-terminal end of SP-1 (Supplementary Fig. 5 ) have the highest potency against HIV-1 with the Gag V370A polymorphism [13] [14] [15] . BVM analogs with C-28 extensions may provide additional, compensatory interactions at the C-terminal end of the 6-helix bundle that are sufficient to prevent protease access to the junction helix cleavage site.
We realize that our interpretation of the binding mechanism of BVM to the 6-helix bundle is based on comparison of MicroED structures with and without the drug. For instance, photoaffinity labeling of detergent-stripped VLPs suggested that BVM may bind in the down orientation 25 . In the context of assembly of the immature hexagonal Gag lattice at the plasma membrane, it may be possible that other factors such as binding of viral RNA may influence the up-down distribution of BVM orientations. Likewise, the orientation may be influenced by the chemical properties of R-group substitutions.
Binding of a single BVM molecule to the Gag hexamer presents challenges for structurebased drug design, but this mode of binding is likely responsible for the efficacy of BVM and related maturation inhibitors that bind to Gag, despite structural heterogeneity inherent in the quasi-hexagonal immature lattice. The CTD-SP1-BVM structure provides additional insights into BVM binding and activity that will inform further development of HIV-1 maturation inhibitors.
The CTD-SP1-BVM structure also demonstrates the capability of MicroED for structurebased drug design and discovery even in challenging cases (i.e., low crystallographic symmetry and diffraction to moderate resolution). The increasing availability of electron microscopes and the ability to obtain microcrystals, either by screening under low dose in an electron microscope or generated by mechanical disruption of larger crystals 26 , make MicroED an attractive option for high-resolution macromolecular structure determination, even for proteins that are far too small for analysis by single-particle cryoEM methods.
METHODS
The protein was expressed and purified as described previously 17 . The crystallization conditions were adapted to grow microcrystals, the data were collected and the structures were solved as described in the Supplementary Methods. Any additional supplementary display items, source data and associated references, are available in the online version of the paper. (Supplementary Fig. 2) . 
SUPPLEMENTARY METHODS

Crystallization of CTD-SP1 and CTD-SP1-BVM. The conditions for growing microcrystals
were adapted from the conditions to grow larger crystals for X-ray crystallography 17 The protein solution was mixed with BVM (e.g. for a 1:8 protein:drug ratio, 10 µl of 1 mg/ml protein were mixed with 10 µl of a solution of 0.64 mM BVM in DMSO/water). An aliquot (1 µl) of the protein/BVM solution was mixed with 2 µl of the well solution. The crystallization plates were incubated at 17° C, and plate-like microcrystals appeared after 1-2 days. The same conditions were used to grow drug-free crystals. Initial screening of the crystals was performed by applying a 3 mm continuous carbon-coated EM grid to the crystallization drop for 90 sec, blotting the grid with filter paper and allowing the grid to dry at room temperature. Successful transfer of the crystals to the grid was first confirmed by light microscopy at 40x magnification ( Supplementary Fig. 1) . The grid was then examined in an FEI TF20 electron microscope operating at 200 kV. The unstained crystals were sufficiently thick to be readily observed from 10K-40K magnification, and successful crystallization was confirmed by electron diffraction.
MicroED sample preparation, data collection and processing. Quantifoil EM grids were glow-discharged for 30 sec on both sides, and the grid was placed onto the crystallization droplet with the carbon-film side facing the droplet. After a 5-10 min incubation, tweezers were used to separate the grid from the droplet, and an additional 1.5 µl of solution from the same droplet was pipetted onto the back side of the grid. The grid was then mounted in an FEI Vitrobot, which was used to plunge-freeze the grid into an ethane slush, with the following settings: blotting time 7-15 15 sec, force 24 and humidity 40%. The grid was transferred to a Gatan 626 cryostage, and continuous rotation MicroED data were recorded using an FEI TF20 microscope equipped with a field emission electron source and a bottom-mounted TVIPS TemCam-F416 CMOS camera operating in rolling shutter mode 20 . Diffraction patterns were recorded using 200 keV electrons with a camera length of 2 m. The electron dose rate was ~0.01 e -/Å 2 /sec, and the crystals were continuously rotated uni-directionally at a rate of 0.062 degrees/sec. 8 sec frames were recorded during the movie, and data typically spanned a tilt range of 0 to 45-60 degrees. Diffraction images were corrected to account for negative pixel values 27 , then they were indexed and integrated in MOSFLM 28 . Integrated intensities from 6 and 5 crystals for the drug-free and BVM-bound samples, respectively, were scaled and merged in AIMLESS 29 .
MicroED structure determination and map calculation. Phases for the BVM-bound and drug-free MicroED reflections were determined by molecular replacement with Phaser 30 using the X-ray structure of hexameric CTD-SP1 (PDB 5I4T) as the search model. Cycles of real space and reciprocal space refinements were performed with Coot 31 and phenix.refine, using electron scattering factors 32 . Torsion-angle NCS restraints were used in the early rounds of refinement. In solving the structure of CTD-SP1-BVM, the drug was never included in the model during refinements that were used for map calculations. Maximum entropy maps were calculated in Phenix and showed plausible improvements in map detail, and thus were used to aid the interpretation of the maps.
We also solved the structure of CTD-SP1-BVM independent of the CTD-SP1 X-ray structure. We generated an all-atom hexameric model of the CTD domain by combination of the X-ray crystal structure of the Gag CTD dimer (PDB 4COP 33 ) and the backbone model of the CTD hexamer from the Gag CA structure determined by a combination of tomography and 16 helical reconstruction. We aligned a copy of the 4COP monomer to each protomer of the 4D1K 33 CTD hexamer and performed molecular replacement with Phaser using the all-atom hexamic CTD as the search model. The top Phaser solution (TFZ = 9.4) showed well-defined density for the CTD and clear α-helical density for SP1. We generated an ideal helix in Coot within the best SP1 density and then generated the initial 6-helix bundle by application of 6-fold NCS. We then performed rounds of building and refinement in Coot and Phenix. The resultant refined BVMbound CTD-SP1 model and associated maps recapitulated those resulting from molecular replacement with the CTD-SP1 X-ray structure.
Electron scattering form factors and Coulombic potential maps. The presence of carboxylic acid groups at each end of BVM makes consideration of the physics of electron scattering relevant to our analysis of BVM binding to Gag, because carboxylates frequently have diminished density in maps derived from cryoEM [34] [35] [36] [37] . Electron diffraction is a result of elastic scattering due to Coloumb forces between the incident electron beam and the crystal, and therefore is dependent on the charge distribution in the crystal (Fig. 2a) . Unlike atomic scattering factors for X-rays, electron scattering factors for some atoms are strongly dependent on scattering angle. In the case of negatively charged oxygen (O -), the atomic scattering factor is negative at low resolution (< 5.5 Å) and positive at higher resolution. This phenomenon results in a negative contribution to acidic side chains in MicroED maps calculated using low-resolution intensities (Fig. S3b,d) 37 . In contrast, maps calculated only with data in the resolution range in which scattering factors for Oare positive are unaffected ( Fig. 3c,e ). The electron scattering factor for uncharged oxygen is fairly constant; therefore, neutralization of acidic side chains by direct interaction with, or proximity to, basic residues eliminates or minimizes the resolution dependence of the electron density of these side chains (Supplementary Fig. 3b,c) . Coulomb potential neutralization of the BVM dimethylsuccinyl carboxylic acid by nearby lysine residues (K359) likely accounts for the presence of density for this moiety.
The absence of acidic side chain density can also be due to mobility and/or radiation damage. Ois more susceptible to radiation damage by electrons than neutral and positively charged atoms, as shown in the analysis of radiation sensitivity of acidic side chains in singleparticle cryoEM experiments 24 . This study also demonstrated that radiation damage to acidic side chains is dose-dependent, and at low total electron doses (< 10 e -/Å 2 ) side chain density for acidic residues is not substantially diminished. The total electron dose in the CTD-SP1 MicroED experiments was 7-10 e -/Å 2 , and therefore, we conclude that radiation damage to acidic side chains occurred but was minimal. Future systematic studies will have to be conducted to conclusively determine the extent of radiation damage in MicroED experiments. a c
